The DNA Damage Response (DDR) field is entering a defining new phase. With PARP inhibitors firmly established in the clinic, attention is turning toward next-generation DDR targets – including ATR, CHK1/2, DNA-PK, and WEE1 – and the biomarker-driven combination strategies that promise to unlock greater selectivity, durability, and reduced toxicity.
This eBook explores the scientific and strategic frontiers transforming DDR drug development – from overcoming resistance mechanisms to designing precision combinations that deliver lasting clinical benefit.
Get exclusive insights from the 9th DDR Inhibitors Summit, where industry leaders, academic innovators, and translational experts come together to shape the next chapter of targeted oncology.
Inside, you’ll discover:
- The most promising novel DDR targets beyond PARP and their clinical potential
- Biomarker-led approaches to improve selectivity and patient outcomes
- Combination strategies designed to overcome resistance and toxicity challenges
- Key perspectives from top biopharma and academic pioneers driving DDR innovation
Access your free copy to see how DDR-focused drug developers are accelerating the future of precision oncology.
About Hanson Wade Group - 9th DDR Inhibitors Summit 2026
Validate Novel Targets & Utilize Biomarker-Driven Combination Strategies to Accelerate the Development of Durable, Selective & Low-Toxicity DDR Therapeutics
Returning to Boston for its 9th year, the DDR Inhibitors Summit is the definitive industry forum for drug developers advancing DNA Damage Response (DDR)-targeted therapies. With PARP inhibitors now clinically validated, the field is rapidly evolving to explore novel DDR targets like ATR, CHK1/2, DNA-PK, and WEE1, alongside smarter biomarker strategies and combination approaches.
This year’s summit is your opportunity to stay ahead of the curve. Across three content-rich days, you’ll uncover translational breakthroughs, hear from biotech innovators & academic pioneers, and gain strategic insights to overcome resistance, enhance selectivity, and accelerate clinical success. With the DDR landscape rapidly expanding, now is the time to connect, collaborate, and shape the future of targeted oncology.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.